Safe and agile experimentation spaces are essential for developing AI-enabled medical devices and digital health innovations. “Living Labs” offer a collaborative environment for testing technologies in near-real-world settings, capturing user perspectives and outcomes, often missed in traditional testing. However, the flexibility of Living Labs often clashes with the European Union’s rigid regulatory frameworks for medical devices that were not designed for digital technologies. We examine this intersection, showing how flexibility in evaluation and patient interaction can coexist with safety guardrails. Our approach integrates technology readiness, preemptive planning, and iterative modifications to bridge innovation and regulation, fostering adaptive health care technology development.
Digital health and AI-enabled technologies hold the promise of addressing gaps in healthcare, but balancing rapid market access with the need for safe, functional, and user-centered solutions remains a challenge [1], [2]. Regulatory requirements for device development and market approval demand detailed documentation and predetermined protocols, which can limit the adaptability developers require for iterative improvement and real-world testing with patients and healthcare professionals [1], [3], [4]—an approach that would be highly beneficial for digital and AI-enabled technologies. As a result, key factors like clinical workflow integration, interoperability, and usability with the real range of in-use devices are often overlooked or addressed in a cursory fashion [5].
29 January 2026 in Journal of Medical Internet Research
The last years have seen an acceleration in the development and uptake of artificial intelligence (AI) systems by “early adopter” hospitals, caught between the pressures to “perform” and “transform” in a struggling health care system. This transformation has raised concerns among health care providers as their voices and location-specific workflows have often been overlooked, resulting in technologies that fail to integrate meaningfully into routine care and worsen rather than improve care processes. How can positive AI implementation be carried out in health care, aligned with European values? Based on a perspective that spans all stakeholders, we have created EURAID (European Responsible AI Development), a practical, human-centric framework for AI development and implementation based on agreed goals and values. We illustrate this approach through the co-development of a narrow-purpose “in-house” AI system, designed to help bridge the AI implementation gap in real-world clinical settings. This example is then expanded to address the broader challenges associated with complex, multiagent AI systems. By portraying all key stakeholders across the AI development life cycle and highlighting their roles and contributions within the process, real use cases, and methods for achieving iterative consensus, we offer a unique practical approach for safe and fast progress in hospital digital transformation in the AI age.
The rapid rise of artificial intelligence (AI) and digital health technologies presents new opportunities for personalized care in multiple sclerosis (MS). However, implementation in routine practice is limited by regulatory hurdles, fragmented infrastructure and a lack of agile real-world evaluation methods. Living Labs (LLs) emerge as dynamic environments for advancing MS care and research, supporting early testing and iterative development of digital tools, while fostering structured collaboration among patients, clinicians, researchers and regulators. In this review, we conceptually frame LLs in MS and provide a concrete, clinic-ready implementation framework for AI-enabled application in real-world practice. Using a digital-based voice task as an exemplar with automated feature extraction, we detail integration patterns and define key performance indicators for feasibility, data quality, usability and clinical utility. We show how this co-designed model can generate decision-relevant evidence, may help shorten time-to-action and embed innovation seamlessly into clinical workflows. Finally, we align LL operations with ethical and regulatory standards and outline strategies to responsibly scale across centres.